继续使用他克莫司局部治疗口腔扁平苔藓患者的癌变风险：一例报告
The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report.
作者信息
Morita Mayu, Asoda Seiji, Tsunoda Kazuyuki, Soma Tomoya, Nakagawa Taneaki, Shirakawa Masayori, Shoji Hirofumi, Yagishita Hisao, Nishikawa Takeji, Kawana Hiromasa
机构信息
Division of Oral and Maxillofacial Surgery, Department of Dentistry and Oral Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Department of Oral Surgery, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
出版信息
Odontology. 2017 Apr;105(2):262-266. doi: 10.1007/s10266-016-0255-4. Epub 2016 Jul 1.
Oral lichen planus is a chronic inflammatory mucocutaneous disease. Topical use of steroids and other immuno-modulating therapies have been tried for this intractable condition. Nowadays, tacrolimus ointment is used more commonly as a choice for treatment. However, a number of discussions have taken place after tacrolimus was reported to be carcinogenic. This report describes a patient who applied tacrolimus ointment to the lower lip after being diagnosed with oral lichen planus in 2008, and whose lesion developed squamous cell carcinoma in 2010. Since the relationship between tacrolimus and cancer development has been reported in only a few cases, including this case report, the clinician must be careful selecting tacrolimus as a second-line treatment for oral lichen planus.
口腔扁平苔藓是一种慢性炎症性黏膜皮肤疾病。针对这种难治性病症，人们尝试过局部使用类固醇及其他免疫调节疗法。如今，他克莫司软膏作为一种治疗选择被更广泛地使用。然而，在有报道称他克莫司具有致癌性之后，引发了诸多讨论。本报告描述了一名患者，该患者于2008年被诊断为口腔扁平苔藓后在下唇涂抹他克莫司软膏，其病损于2010年发展为鳞状细胞癌。由于包括本病例报告在内，仅有少数病例报道了他克莫司与癌症发生之间的关系，临床医生在选择他克莫司作为口腔扁平苔藓的二线治疗药物时必须谨慎。
Zotero 插件